Stryker Corporation's shares dropped 8.8% after CFO Preston Wells disclosed that a manufacturing problem in its Peripheral Vascular unit, previously thought resolved, is continuing into Q4 2026. This revelation wiped out over $10 billion in market value and sparked an investigation by Hagens Berman into whether Stryker fully disclosed the issue to investors. The ongoing supply disruptions have impacted sales and new business opportunities, raising concerns about the company's transparency and future performance.
Stryker Corporation's shares are down 0.81% on Pluang, trading at USD 273.26 as of Oct 02, 2026 01:31 WIB. The stock's market cap stands at $105.63 billion, with all current Pluang orders on the buy side.
Stryker Corp. is under investigation by Pomerantz LLP for potential securities fraud after the company's CEO disclosed unresolved manufacturing problems affecting inventory supply in its peripheral vascular business. This issue, initially expected to...
Stryker Corporation reported supply disruptions in Q2 2026 that led to significant backorders and lost sales, causing its shares to fall 6.43% on July 31, 2026. The company initially expected the issue to resolve by Q3, but CFO Preston Wells later re...
The Law Offices of Frank R. Cruz is investigating Stryker Corporation for possible securities law violations after supply disruptions led to significant backorders and lost sales, causing the stock to drop sharply in July and September 2026. The comp...
Stryker has received FDA 510(k) clearance for Sonopet 3, its latest ultrasonic bone and soft tissue removal platform developed with surgeon input. The device offers enhanced power, precision, and versatility, featuring new technologies like RISE for ...
